Precision oncology

Precision oncology is an integrative therapeutic and diagnostic framework for cancer care that uses advanced analytics to match treatment to tumor biology, and it is described as a transformative approach in oncology. It combines diagnostics and therapeutics, with next generation sequencing serving as a dual-purpose bridge between molecular profiling and treatment selection. The framework also incorporates multi omics data, especially in gastrointestinal cancers, where emerging omics evidence suggests a meaningful shift toward more individualized clinical practice. Therapeutically, it includes modalities such as car t cell therapy, crispr, and nanotechnology based delivery, reflecting a broad move toward targeted intervention rather than one-size-fits-all treatment. Recent reviews emphasize that this convergence of analytical techniques and cancer therapeutics is reshaping how precision oncology is implemented in the clinic.

Gastrointestinal cancers

  • A 2026 Molecular Cancer review (PMID:41992238) highlighted that emerging multi omics data are driving a meaningful shift toward precision oncology in gastrointestinal tumor biology and clinical practice.
  • The same review (PMID:41992238) frames precision oncology as a clinical framework increasingly informed by integrated omics-based tumor characterization.
  • The review suggests that omics-guided stratification is becoming central to individualized management of gastrointestinal cancers. (PMID:41992238)

Diagnostics and therapeutic integration

  • A 2026 Critical Reviews in Analytical Chemistry review (PMID:41983744) described precision oncology as an approach integrating advanced diagnostics and therapeutics for targeted cancer care.
  • next generation sequencing was presented as a dual-purpose tool that bridges diagnostic profiling and therapeutic decision-making within precision oncology. (PMID:41983744)
  • The review emphasized combining state-of-the-art analytical technologies to support a transformative cancer-treatment framework. (PMID:41983744)

Targeted and emerging therapeutics